This is an editorial. The purpose is to point out the limits of the empirical literature linking launch delays of new drugs with the regulation of entry. We find four main problems related to the main conclusions of the literature. We think that these limits should be aknowledged in the international debate on the regulation of drugs approvals.
Should we really worry about "launch delays" in OECD countries?
GHISLANDI, SIMONE
2007
Abstract
This is an editorial. The purpose is to point out the limits of the empirical literature linking launch delays of new drugs with the regulation of entry. We find four main problems related to the main conclusions of the literature. We think that these limits should be aknowledged in the international debate on the regulation of drugs approvals.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
